期刊文献+

二甲双胍对具核梭杆菌与结直肠癌的影响

Effect of Metformin on Clostridium Nucleatum and Colorectal Cancer
原文传递
导出
摘要 目的 探讨二甲双胍对具核梭杆菌(Fn)与结直肠癌(CRC)细胞增殖和E-cadherin蛋白表达的影响。方法 采用MTT法测定CRC细胞24 h、48 h、72 h的增殖能力。用Western blotting检测法检测各组E-cadherin蛋白表达情况。结果 二甲双胍与联合组SW480细胞增殖活力明显下调(24 h:P=0.002;48 h:P=0.000;72 h:P=0.000),二甲双胍组和联合组E-cadherin蛋白表达量较对照组和Fn组均明显升高(P<0.05)。结论 二甲双胍可能通过促使肿瘤细胞与E-cadherin结合,抑制Fn附着和侵入上皮细胞,从而降低CRC的发生和浸润转移。 Objective To investigate the effects of metformin on Clostridium nucleatum(FN) and the proliferation and E-cadherin protein expression of colorectal cancer(CRC) cells. Methods MTT assay was used to determine the proliferation of colorectal cancer cells. Western blotting was used to detect the expression of E-Cadherin protein in each group for statistical analysis. Results The proliferation activity of SW480 cells in metformin and combination group were significantly down-regulated(24 h: P=0.002;48 h: P=0.000;72 h: P=0.000);the expression of e-cadherin protein in metformin group and combined group were significantly lower than that in control group and Fn group(P<0.05). Conclusion Metformin may inhibit FN attachment and invasion into epithelial cells by promoting the combination of tumor cells with E-cadherin, thereby reducing the occurrence, infiltration and metastasis of CRC.
作者 魏攀凤 张小燕 WEI Pan-Feng;ZHANG Xiao-Yan(Department of Basic Medical Sciences,Quanzhou Medical College,Quanzhou 362000,China)
出处 《中国药物经济学》 2022年第8期104-106,110,共4页 China Journal of Pharmaceutical Economics
基金 福建省泉州市科技计划项目(2018Z174)。
关键词 二甲双胍 具核梭杆菌 结直肠癌 Metformin Fusobacterium nucleatum Colorectal cancer
  • 相关文献

参考文献10

二级参考文献96

  • 1徐希民,管纯梅,孙建丽,李朱福,诸月琴.血清维生素A和维生素C水平与大肠癌发病关系的探讨[J].实用肿瘤杂志,1989,4(3):153-155. 被引量:3
  • 2杨工,高玉堂,季步天,金凡,高汝聂,郑树.结、直肠癌与营养因素的流行病学研究[J].中华流行病学杂志,1994,15(5):299-303. 被引量:31
  • 3Muzny DM,Bainbridge MN,Chang K,et al.Comprehensive molecular characterization of human colon and rectal cancer[J].Nature,2012,487(7407):330-337.
  • 4Courtney RJ,Paul CL,Carey ML,et al.A population-based cross-sectional study of colorectal cancer screening practices of first-degree relatives of colorectal cancer patients[J].BMC Cancer,2013,13(1):1-11.
  • 5Dahan L,Norguet E,Etienne-Grimaldi MC,et al.Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer[J].BMC Cancer,2011,11(1):496.
  • 6Adelsten BA,Dobbins TA,Harris CA,et al.A systematic review and meta-analysis of KRAS status as determinant of response to anti-EGFR antibodies and impact of partner chemotherapy in metastatic colorectal cancer[J].Eur J Cancer,2011,47(9):1343-1354.
  • 7Lin AY,Buckley NS,Lu AT,et al.Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy:a systematic review and meta-analysis[J].Clin Colorectal Cancer,2011,10(1):63-69.
  • 8Greenwald P,Lanza E,Eddy GA,et al.Dietary fiber in the reduction of colon cancer risk[J].J Am Diet Assoc,1987,87(9):1178-1188.
  • 9Ghadirian P,Lacroix A,Maisonneuve P,et al.Nutritional factors and colon carcinoma:a case-control study involving French Canadians in Montreal,Quebec,Canada[J].Cancer,1997,80(5):858-864.
  • 10Hibler EA,Hu CC,Jurutka PW,et al.Polymorphic variation in the GC and CASR genes and associations with vitamin D metabolite concentration and metachronous colorectal neoplasia[J].Cancer,2012,21(2):368-375.

共引文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部